Lifetime cost-effectiveness of skin cancer prevention through promotion of daily sunscreen use

Value in Health

Volumn 15, Issue 2, 2012, Pages 261-268

  Hirst, Nicholas G ^a   Gordon, Louisa G ^a   Scuffham, Paul A ^a   Green, Adele C ^a,b,c  

^a GRIFFITH UNIVERSITY   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

cost effectiveness; health care costs; melanoma; primary prevention; squamous cell carcinoma; sunscreen

Indexed keywords

SUNSCREEN;

ARTICLE; AUSTRALIA; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CAUCASIAN; CONSUMER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; GOVERNMENT; HEALTH CARE COST; HEALTH PROMOTION; HEALTH STATUS; HUMAN; MELANOMA; OUTCOMES RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; AUSTRALIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH CARE COSTS; HEALTH PROMOTION; HUMANS; MALE; MARKOV CHAINS; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PRIMARY PREVENTION; SKIN NEOPLASMS; SUNSCREENING AGENTS;

EID: 84858695370     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.10.009     Document Type: Article

References (56)

1. National Cancer Institute. Melanoma. 2010. Available from: http://www.cancer.gov/cancertopics/types/melanoma. [Accessed October 13, 2010].
2. Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality Books. Canberra, Australia: Australian Institute of Health and Welfare, 2010.
3. Australian Institute of Health and Welfare. Health system expenditures on cancer and other neoplasms in Australia, 2000-01. AIHW Cat. No. HWE 29. In: Health and Welfare Expenditure Series No.22. Canberra, Australia: Australian Institute of Health and Welfare, 2005.
4. Housman TS, Feldman SR, Williford PM, Fleischer AB, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425-9. (Pubitemid 36337080)
5. Staples MP, Elwood M, Burton RC, Williams JL, et al. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006;184:6-10. (Pubitemid 43149790)
6. Holmes C, Foley P, Freeman M, Chong A. Solar keratosis: epidemiology, pathogenesis, presentation and treatment. Australas J Dermatol 2007;48:67-74.
7. Darlington S, Williams G, Neale R, Frost C, Green A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003;139:451-5. (Pubitemid 36427609)
8. Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics 2009;27:451-64.
9. Young C. Solar ultraviolet radiation and skin cancer. Occup Med (Lond) 2009;59:82-8.
10. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001;12:69-82. (Pubitemid 32125902)
11. US Preventive Services Task Force. Screening for skin cancer, recommendations and rationale. Am J Prev Med 2001;20:44-6.
12. National Radiological Protection Board UK. Health Effects from Ultraviolet Radiation: Report of an Advisory Group on Non-Ionising Radiation. 2008.
13. Cancer Council Australia and Australasian College of Dermatologists. Position statement: screening and early detection of skin cancer. 2007. Available from: http://www.cancer.org.au/policy/positionstatements/sunsmart/ screeningandearlydetectionofskincancer.htm. [Accessed September 3, 2010].
14. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329:1147-51. (Pubitemid 23295456)
15. Green A, Williams G, Neale R, Hart V, et al. Daily sunscreen application and betacarotene supplementation in prevention of basalcell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999;354:723-9. Erratum: Lancet 1999;354:1038. (Pubitemid 29438440)
16. Australian Institute of Health and Welfare (AIHW) and Australasian Associations of Cancer Registries (AACR). Cancer in Australia: an overview 2006. In: Cancer Series No. 37. Canberra, Australia: Australian Institute of Health and Welfare, 2007.
17. Lucas RM, Repacholi MH, McMichael AJ. Is the current public health message on UV exposure correct? Bull World Health Organ 2006;84: 485-91. (Pubitemid 43845449)
18. Montague M, Borland R, Sinclair C. Slip! Slop! Slap! and SunSmart, 1980-2000: skin cancer control and 20 years of population-based campaigning. Health Educ Behav 2001;28:290-305. (Pubitemid 33602890)
19. Coory M, Baade P, Aitken J, Smithers M, et al. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control 2006;17:21-7. (Pubitemid 43083666)
20. Linder JA, Tice JA. Betacarotene and sunscreen use. Lancet 1999; 354:2164.
21. Gordon LG, Scuffham PA, Van der Pols JC, McBride P, et al. Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol 2009;129:2766-71.
22. Neale RE, Green AC. Measuring behavioral interventions by questionnaires and prospective diaries: an example of sunscreen use. Epidemiology 2002;13:224-7. (Pubitemid 34160499)
23. Neale RE, Williams G, Green AC. Application patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol Res 2002;138:1319-25.
24. Green AC, Battistutta D, Hart V, Leslie D, et al. The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: design and baseline characteristics of participants. Contr Clin Trials 1994;15:512-22. (Pubitemid 24359727)
25. van der Pols JC, Williams GM, Pandeya M, Logan V, Green AC, et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15:2456-8.
26. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29:257-63.
27. Weinstein MC, O'Brien BJ, Hornberger J, Jackson J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
28. American Joint Committee on Cancer. Cancer Staging Manual. NY: Springer Publishing, 2002.
29. AIHW. Cancer incidence data cubes. Cancer Series 2009. Available from: http://www.aihw.gov.au/cancer/data/datacubes/index.cfm. [Accessed May 23, 2009].
30. Ferrone CR, Porat LB, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:1647-54. (Pubitemid 41407357)
31. Balch CM, Soong S-J, Gershenwald JE, Thompson JF, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34. (Pubitemid 32786275)
32. Australian Bureau of Statistics. Life Tables, Australia, 2003 to 2005. Canberra, Australia: Australian Bureau of Statistics, 2007.
33. Bendeck S, Hadley JC, Bonaccorsi P, Brown KM, et al. Can melanoma patients predict the quality of life impact of an alternate melanoma stage?In: CEA: Methods and Applications: Health Services Research. Atlanta: Society for Medical Decision Making, 2004.
34. Beusterien KM, Ackerman SJ, Plante K, Glaspy J, et al. The healthrelated quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. J Support Oncol 2003;11:304-12. (Pubitemid 36723558)
35. Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001;19:812-23. (Pubitemid 32119097)
36. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: A Tool for Decision Making. Washington, DC: National Academy Press, 2000.
37. Morton RL, Howard K, Thompson JF. The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma. Ann Surg Oncol 2009;16: 929-40.
38. Access Economics. Cost of Cancer in NSW. Kings Cross, Australia: The Cancer Council NSW, 2007.
39. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997;15:2351-8. (Pubitemid 27251138)
40. Australian Bureau of Statistics. 2010. Available from: http://www. abs.gov.au/. [Accessed March 11, 2010].
41. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 2008;28:713-22.
42. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. In: Gray A, Briggs AH, eds., Handbooks in Health Economic Evaluation Series. Oxford: Oxford University Press, 2006.
43. Pandeya N, Purdie DM, Green AC, Williams G, et al. Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. Am J Epidemiol 2005;161:748-54.
44. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115:273-7. (Pubitemid 30637198)
45. Neale R, Williams G, Green A. Applications patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol 2002;138:1319-25.
46. Mayor S. NICE recommends greater use of sunscreens at school and work to prevent skin cancer. BMJ 2010;341:c4641.
47. International Agency for Research on Cancer. Handbooks of Cancer Prevention, Vol. 5: Sunscreens. Lyon, France: International Agency for Research on Cancer, 2001.
48. Diffey BL. Sunscreens as a preventative measure in melanoma: an evidence-based approach or the precautionary principle? Br J Dermatol 2009;161(Suppl. 3):25-7.
49. Lautenschlager S, Wulf HC, Pittelkow MR. Photoprotection. Lancet 2007;370:528-37. (Pubitemid 47212348)
50. Wright CY, Reeder AI. Youth solar ultraviolet radiation exposure, concurrent activities and sun-protective practices: a review. Photochem Photobiol 2005;81:1331-42. (Pubitemid 43035840)
51. McBride P. Cutaneous squamous cell carcinoma and its determinants, in School of Population Health [thesis]. Brisbane, Australia: University of Queensland, 2009.
52. Grant WB, Cross HS, Garland CF, Gorham ED, et al. Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog Biophys Mol Biol 2009;99:104-13.
53. Norval M, Wulf HC. Does chronic sunscreen use reduce vitamin D production to insufficient levels? Br J Dermatol 2009;161:732-6.
54. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
55. Shih ST, Carter R, Sinclair C, Mihalopoulos C, Vos T. Economic evaluation of skin cancer prevention in Australia. Prev Med 2009;49: 449-53.
56. Carter R, Marks R, Hill D. Could a national skin cancer primary prevention campaign in Australia be worthwhile? An economic perspective. Health Promot Inter 1999;14:73-81.